STA
ACAD icon

Summit Trail Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Summit Trail Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-335
Closed -$10K – 423
2017
Q4 		$10K Buy
+335
New +$10.7K ﹤0.01% 1214

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Summit Trail Advisors's ACAD Position: Q1 2018 in Review

Summit Trail Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2018, closing a stake of 335 shares — an estimated $10K sold.

Summit Trail Advisors first reported a position in ACAD in Q4 2017 and held it in 1 quarter. The position peaked at $10K in Q4 2017. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

  • Summit Trail Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 335 Acadia Pharmaceuticals shares in Q1 2018, an estimated $10K.
  • Summit Trail Advisors first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Acadia Pharmaceuticals position peaked at $10K in Q4 2017.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.